$42.00
Additional information
| Active substance | Pioglitazone | 
|---|---|
| Water Retention | Yes | 
| Hepatotoxicity | Low risk, but monitoring liver function is recommended | 
| Lab Test | Monitoring blood glucose and liver function tests | 
| Also known as | Pioglitazone hydrochloride | 
| Blood pressure | Could potentially cause fluid retention which might increase blood pressure | 
| Trade name | Actos | 
| FORM | 28 pills x 15 mg | 
| Storage conditions | Store at room temperature, protect from moisture and light | 
| Chemical name | 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione | 
| Formula | C19H20N2O3S | 
| Substance class | Thiazolidinedione | 
| Main action | Antidiabetic, insulin sensitizer | 
| Half-life | 3-7 hours | 
| Dosage (medical) | Typically 15-45 mg per day | 
| Dosage (sports) | Not applicable | 
| Effects | Lowers blood glucose, increases insulin sensitivity | 
| Side effects | Weight gain, edema, heart failure, increased risk of bladder cancer, bone fractures | 
| Use in sports | Not typically used in sports | 
| Manufacturer | Takeda | 





